Literature DB >> 11493692

BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor.

L Zheng1, L A Annab, C A Afshari, W H Lee, T G Boyer.   

Abstract

Mutational inactivation of BRCA1 confers a cumulative lifetime risk of breast and ovarian cancers. However, the underlying basis for the tissue-restricted tumor-suppressive properties of BRCA1 remains poorly defined. Here we show that BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor alpha (ERalpha), a principal determinant of the growth, differentiation, and normal functional status of breasts and ovaries. In Brca1-null mouse embryo fibroblasts and BRCA1-deficient human ovarian cancer cells, ERalpha exhibited ligand-independent transcriptional activity that was not observed in Brca1-proficient cells. Ectopic expression in Brca1-deficient cells of wild-type BRCA1, but not clinically validated BRCA1 missense mutants, restored ligand-independent repression of ERalpha in a manner dependent upon apparent histone deacetylase activity. In estrogen-dependent human breast cancer cells, chromatin immunoprecipitation analysis revealed the association of BRCA1 with ERalpha at endogenous estrogen-response elements before, but not after estrogen stimulation. Collectively, these results reveal BRCA1 to be a ligand-reversible barrier to transcriptional activation by unliganded promoter-bound ERalpha and suggest a possible mechanism by which functional inactivation of BRCA1 could promote tumorigenesis through inappropriate hormonal regulation of mammary and ovarian epithelial cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493692      PMCID: PMC55496          DOI: 10.1073/pnas.171174298

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

Review 1.  Estrogen receptor interaction with co-activators and co-repressors.

Authors:  C M Klinge
Journal:  Steroids       Date:  2000-05       Impact factor: 2.668

2.  Role of direct interaction in BRCA1 inhibition of estrogen receptor activity.

Authors:  S Fan; Y X Ma; C Wang; R Q Yuan; Q Meng; J A Wang; M Erdos; I D Goldberg; P Webb; P J Kushner; R G Pestell; E M Rosen
Journal:  Oncogene       Date:  2001-01-04       Impact factor: 9.867

3.  Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1.

Authors:  L Zheng; H Pan; S Li; A Flesken-Nikitin; P L Chen; T G Boyer; W H Lee
Journal:  Mol Cell       Date:  2000-10       Impact factor: 17.970

Review 4.  Lessons learned from BRCA1 and BRCA2.

Authors:  L Zheng; S Li; T G Boyer; W H Lee
Journal:  Oncogene       Date:  2000-12-11       Impact factor: 9.867

5.  Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors.

Authors:  K R Geisinger; T E Kute; M J Pettenati; C E Welander; Y Dennard; L A Collins; M E Berens
Journal:  Cancer       Date:  1989-01-15       Impact factor: 6.860

6.  Brca1 controls homology-directed DNA repair.

Authors:  M E Moynahan; J W Chiu; B H Koller; M Jasin
Journal:  Mol Cell       Date:  1999-10       Impact factor: 17.970

Review 7.  Genetic and hormonal risk factors in breast cancer.

Authors:  A M Martin; B L Weber
Journal:  J Natl Cancer Inst       Date:  2000-07-19       Impact factor: 13.506

Review 8.  Estrogens, BRCA1, and breast cancer.

Authors:  L Hilakivi-Clarke
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

Review 9.  Is estradiol a genotoxic mutagenic carcinogen?

Authors:  J G Liehr
Journal:  Endocr Rev       Date:  2000-02       Impact factor: 19.871

10.  Increased cell survival by inhibition of BRCA1 using an antisense approach in an estrogen responsive ovarian carcinoma cell line.

Authors:  L A Annab; R E Hawkins; G Solomon; J C Barrett; C A Afshari
Journal:  Breast Cancer Res       Date:  2000-02-21       Impact factor: 6.466

View more
  55 in total

1.  Degradation of transcription repressor ZBRK1 through the ubiquitin-proteasome pathway relieves repression of Gadd45a upon DNA damage.

Authors:  Jeanho Yun; Wen-Hwa Lee
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

2.  JunB potentiates function of BRCA1 activation domain 1 (AD1) through a coiled-coil-mediated interaction.

Authors:  Yan-Fen Hu; Rong Li
Journal:  Genes Dev       Date:  2002-06-15       Impact factor: 11.361

3.  Loss of BRCA1 leads to an increased sensitivity to Bisphenol A.

Authors:  Laundette P Jones; Aishia Sampson; Hyo Jin Kang; Hee Jeong Kim; Yong-Weon Yi; Sun Young Kwon; Janice K Babus; Antai Wang; Insoo Bae
Journal:  Toxicol Lett       Date:  2010-09-22       Impact factor: 4.372

4.  Quantitative proteomic identification of the BRCA1 ubiquitination substrates.

Authors:  Meihua Song; Kevin Hakala; Susan T Weintraub; Yuzuru Shiio
Journal:  J Proteome Res       Date:  2011-10-11       Impact factor: 4.466

5.  Estrogen receptors inhibit Smad3 transcriptional activity through Ap-1 transcription factors.

Authors:  Tracy Cherlet; Leigh C Murphy
Journal:  Mol Cell Biochem       Date:  2007-07-28       Impact factor: 3.396

6.  A mechanism for transcriptional repression dependent on the BRCA1 E3 ubiquitin ligase.

Authors:  Andrew A Horwitz; El Bachir Affar; George F Heine; Yang Shi; Jeffrey D Parvin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-09       Impact factor: 11.205

7.  Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?

Authors:  Rachel Mitchell; Lela Buckingham; Melody Cobleigh; Jacob Rotmensch; Kelly Burgess; Lydia Usha
Journal:  PLoS One       Date:  2018-04-16       Impact factor: 3.240

8.  The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.

Authors:  Yongxian Ma; Pragati Katiyar; Laundette P Jones; Saijun Fan; Yiyu Zhang; Priscilla A Furth; Eliot M Rosen
Journal:  Mol Endocrinol       Date:  2005-08-18

Review 9.  Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy.

Authors:  Yingmei Wang; Ping Ji; Jinsong Liu; Russell R Broaddus; Fengxia Xue; Wei Zhang
Journal:  Mol Cancer       Date:  2009-02-13       Impact factor: 27.401

Review 10.  BRCA1, hormone, and tissue-specific tumor suppression.

Authors:  Yanfen Hu
Journal:  Int J Biol Sci       Date:  2008-12-13       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.